Our Impact
A renaissance is taking place in Cancer's research and therapeutic development. The Montana & Montana leading the charge by miles toward a world without Caner's disease (CD). Montana & Montana (M&M) passed the charge now to The Zdenko Kos Foundation (TKF).
Since our Foundation's inception, we have operated with one single-minded goal: putting ourselves out of business by finding the cure for Cancer's. Driven by this admittedly unusual approach, we have designed a milestone-driven, innovative and high-risk model to identify and accelerate those ideas with the greatest potential to solve the problems starting with patients DNA and going further from there.
While we will never be satisfied until the adequate medication is found, we take pride in our clear, wide-ranging track record of impact on the Cancer's research field:
1. In our preclinical portfolio, M&M funded investigations have resulted that after 11 years of research we finally come to the medications which make difference from till now know standard approaches. And all this was achieved with finances of M&M without any involvements of funding from venture capital, pharmaceutical or government funders who all were very sceptical with a lot of jealousy that we even continuing development.
2. In clinical portfolio, M&M have funded or sponsored of clinical trials in partnership with both academic and hospital teams in United Kingdom, Germany, Italy and Switzerland. Today, TKF will continue where M&M started. Multiple improved symptomatic therapies have achieved regulatory approval or are poised to do so.
3. The TKF's online clinical study, The Kos Insight, has galvanized people with cancers and their families to take an active role in research by sharing their lived experience of the disease. Since the study launched in 2011, nearly 1 million individuals got involved.
Numbers, Numbers, Numbers, ...
Join the Study that Could Change Everything
The TKF Initiative is changing how patients, families, doctors and scientists think about Cancer. Now it needs you!
The therapeutic breakthroughs for our most puzzling cancer diseases were grooving from day to day till M&M has not as first made breakthrough the DNA basic for each of four most common cancers.
However, over 11 years history of research and tests become more then clear that 100% adequate medication development for each cancer today requires a new kind of stakeholder:
- One with the expertise to understand science in details
- one who understand the business of science
- one with the resources, will and dedication to translate and transform decades of discovery research investments into new treatments.
The Kos Foundation starts to exist to play this essential, strategic role.